Abstract: Provided are a composition containing fermented pine extract that prevents skin wrinkles, improves skin barrier function, prevents hair loss, promotes hair growth and improves hair health, and a method for manufacturing the same. According to an embodiment of the present invention, a method for manufacturing a composition containing fermented pine extract that prevents skin wrinkle, improves skin barrier function, prevents hair loss, promotes hair growth and improves hair health is provided. The method includes the steps of extracting extract from a pine tree, producing pine extract by processing the extract, and producing fermented pine extract by fermenting the pine extract.

Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Abstract: Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.

Abstract: The present invention relates to a novel organic electroluminescent compound, layer and an organic electroluminescent device using the same. Said organic luminescent compound provides an organic light emitting layer and/or device which has high luminous efficiency and a long operation lifetime and requires a low driving voltage improving power efficiency and power consumption.

Abstract: The present invention relates to a novel organic electroluminescent compound, layer and an organic electroluminescent device using the same. Said organic luminescent compound provides an organic light emitting layer and/or device which has high luminous efficiency and a long, operation lifetime and requires a low driving voltage improving power efficiency and power consumption.

Abstract: The present invention relates to electroluminescent compounds of formula 1 where A and/or B represent fluorene, carbazole, dibenzo[b,d]thiophene or dibenzo[b,d]furan derivatives and L1, X1, Ar1, Ar2, R5, R6 and R7 are as defined herein, and organic electroluminescent devices comprising the same. The compounds according to the present invention have an advantage in manufacturing an organic electroluminescent device which has a high luminous efficiency and a long operational lifetime.

Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using the same. Said organic luminescent compound provides an organic electroluminescent device which has high luminous efficiency and a long operation lifetime and requires a low driving voltage improving power efficiency and power consumption.

Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention is better in luminous efficiency and lifespan characteristics compared to conventional materials. Using the compounds of the present invention, it is possible to manufacture an OLED device with a long operational lifespan. In addition, the compounds can improve the power efficiency of the device to reduce overall power consumption.

Abstract: Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.

Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.

Abstract: The present invention relates to electroluminescent compounds of formula 1 where A and/or B represent fluorene, carbazole, dibenzo[b,d]thiophene or dibenzo[b,d]furan derivatives and L1, X1, Ar1, Ar2, R5, R6 and R7 are as defined herein, and organic electroluminescent devices comprising the same. The compounds according to the present invention have an advantage in manufacturing an organic electroluminescent device which has a high luminous efficiency and a long operational lifetime.

Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using the same. Said organic luminescent compound provides an organic electroluminescent device which has high luminous efficiency and a long operation lifetime and requires a low driving voltage improving power efficiency and power consumption.

Abstract: Provided are novel compounds in accordance with Formula I for an organic electronic material and an organic electroluminescent device using same. The compound for an organic electronic material disclosed herein exhibits high electron transport efficiency and thus prevents crystallization upon manufacturing a device, and also facilitates the formation of a layer, thus improving current properties of the device. Thereby, OLED devices having improved power efficiency as well as reduced operating voltage can be manufactured.

Abstract: Disclosed is a percutaneous absorption preparation for treatment of dementia that comprises rivastigmine or its pharmaceutically acceptable salt as an active ingredient, a styrene-isoprene-styrene block copolymer, a tackifier resin, and a plasticizer, which preparation contains a small amount of rivastigmine but allows a sufficient amount of the active ingredient penetrated into the skin to achieve an effective treatment of dementia.

Abstract: The patch for tooth whitening of the present invention includes a tooth-adhering layer (1) containing erodible polymer complexes formed by hydrogen bonding of a polymer with a carboxyl group (—COOH) and a polymer with a carbonyl group (—C?O) or ether group (—O—) and a tooth whitening agent; and an erosion rate-controlling layer (2) containing a mixture of a hydrophilic polymer and a film-forming polymer, wherein the patch is in a film form and is characterized by being eroded until extinguished after releasing the tooth whitening agent. When applied to the teeth, the patch releases a peroxide tooth-whitening agent while being hydrated by water in the mouth during a prescribed period, and thereafter, eroded until extinguished, thereby not requiring an additional detaching work from the teeth. Therefore, the patch is convenient in use and greatly reduces an obstruction sensation. Moreover, the patch has an excellent whitening effect.

Abstract: The patch for tooth whitening of the present invention includes a tooth-adhering layer (1) containing erodible polymer complexes formed by hydrogen bonding of a polymer with a carboxyl group (—COOH) and a polymer with a carbonyl group (—C═O) or ether group (—O—) and a tooth whitening agent; and an erosion rate-controlling layer (2) containing a mixture of a hydrophilic polymer and a film-forming polymer, wherein the patch is in a film form and is characterized by being eroded until extinguished after releasing the tooth whitening agent. When applied to the teeth, the patch releases a peroxide tooth-whitening agent while being hydrated by water in the mouth during a prescribed period, and thereafter, eroded until extinguished, thereby not requiring an additional detaching work from the teeth. Therefore, the patch is convenient in use and greatly reduces an obstruction sensation. Moreover, the patch has an excellent whitening effect.